Table 1.
M-protein and serum free light-chain levels during IL-1 inhibition
| Patient | Sex | Treatment | M-protein | Serum free light-chains | |||
|---|---|---|---|---|---|---|---|
| number | subtype | g/L | kappa (mg/l) | lambda (mg/l) | Ratio κ / λ | ||
| 1 | M | Anakinra | IgMκ & IgMλ | 10.1 | 14.4 | 46.8 | 0.31 |
| None (Day 4 after anakinra withdrawal) | 7.7 | 14.7 | 53.9 | 0.27 | |||
| Canakinumab day 28 | 10.6 | 18.6 | 51.0 | 0.36 | |||
| Relapse (post-canakinumab) | 9.3 | ||||||
| 2 | F | None (pre-anakinra) | IgGκ | 6.8 | 88.3 | 12.4 | 7.12 |
| Anakinra | 5 | 59.9 | 9.4 | 6.35 | |||
| None (day 5 after anakinra withdrawal) | 4.1 | 69 | 13.5 | 5.11 | |||
| Canakinumab Day 28 | 4.3 | 59.1 | 11.6 | 5.09 | |||
| Relapse (post-canakinumab) | 3.7 | 78.4 | 12.2 | 6.43 | |||
| 3 | M | None (day 5 after anakinra withdrawal) | IgMκ | 2.7 | |||
| Canakinumab day 28 | 3.5 | 19.1 | 19.8 | 0.96 | |||
| 4 | M | Anakinra | IgGκ | 2.9 | |||
| None (day 5 after anakinra withdrawal) | 2.8 | ||||||
| Canakinumab day 28 | 3.2 | 14 | 10.3 | 1.36 | |||
| Relapse (post-canakinumab) | 2.5 | ||||||
| 5 | M | Anakinra | IgMκ | 4.4 | |||
| None (day 6 after anakinra withdrawal) | 4.5 | 19.4 | 12.4 | 1.56 | |||
| Canakinumab day 28 | 5 | ||||||
| Relapse (post-canakinumab) | |||||||
| 6 | M | Anakinra | IgMκ | 6.8 | 25.5 | 20.6 | 1.24 |
| None (day 4 after anakinra withdrawal) | 6.1 | 29.2 | 15.8 | 1.85 | |||
| Canakinumab day 28 | 5.6 | 29.3 | 17.9 | 1.64 | |||
| Relapse (post-canakinumab) | 6.3 | ||||||
| 7 | F | Anakinra | IgGκ | n.d. | |||
| None (day 3 after anakinra withdrawal) | n.d. | 15.3 | 15.1 | 1.01 | |||
| Canakinumab day 28 | n.d. | ||||||
| Relapse (post-canakinumab) | n.d. | ||||||
| 8 | M | Anakinra | IgGκ | n.d. | 17 | 13.5 | 1.26 |
| None (day 5 after anakinra withdrawal) | n.d. | 26.9 | 18.7 | 1.44 | |||
| Canakinumab day 14 | p.n.q. | 18.4 | 18.1 | 1.02 | |||
| Canakinumab day 28 (relapse) | p.n.q. | 23.9 | 23.2 | 1.03 | |||
Free light-chains in the serum were measured with the Freelight assay, reference values: serum free kappa chains (3.3−19.4 mg/l); serum free kappa chains (5.7−26.3 mg/l); ratio kappa/labda light-chains (0.26−1.65). Abnormal values are indicated in bold. n.d. not detectable; p.n.q. present but not quantifiable